X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Elder Pharma with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ELDER PHARMA   ACTAVIS
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
ACTAVIS
Dec-14
ELDER PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs38017,369-   
Low Rs18810,595-   
Sales per share (Unadj.) Rs491.23,127.7-  
Earnings per share (Unadj.) Rs-3.2-390.3-  
Cash flow per share (Unadj.) Rs14.4287.0-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs376.56,783.9-  
Shares outstanding (eoy) m20.54265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.64.5 12.9%   
Avg P/E ratio x-89.3-35.8 249.2%  
P/CF ratio (eoy) x19.748.7 40.5%  
Price / Book Value ratio x0.82.1 36.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m5,8333,717,796 0.2%   
No. of employees `000NA21.6 0.0%   
Total wages/salary Rs m2,1790-   
Avg. sales/employee Rs ThNM38,502.7-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM-4,804.7-  
INCOME DATA
Net Sales Rs m10,089831,658 1.2%  
Other income Rs m257-2,076 -12.4%   
Total revenues Rs m10,346829,582 1.2%   
Gross profit Rs m-792106,838 -0.7%  
Depreciation Rs m361180,084 0.2%   
Interest Rs m2,75626,232 10.5%   
Profit before tax Rs m-3,653-101,554 3.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,713-7,449 -49.8%   
Tax Rs m125-5,221 -2.4%   
Profit after tax Rs m-65-103,782 0.1%  
Gross profit margin %-7.812.8 -61.1%  
Effective tax rate %-3.45.1 -66.6%   
Net profit margin %-0.6-12.5 5.2%  
BALANCE SHEET DATA
Current assets Rs m9,240438,177 2.1%   
Current liabilities Rs m9,998319,560 3.1%   
Net working cap to sales %-7.514.3 -52.7%  
Current ratio x0.91.4 67.4%  
Inventory Days Days4658 79.8%  
Debtors Days Days6066 90.4%  
Net fixed assets Rs m10,124101,554 10.0%   
Share capital Rs m2060-   
"Free" reserves Rs m5,5820-   
Net worth Rs m7,7341,803,835 0.4%   
Long term debt Rs m4,889945,245 0.5%   
Total assets Rs m22,8823,305,836 0.7%  
Interest coverage x-0.3-2.9 11.3%   
Debt to equity ratio x0.60.5 120.6%  
Sales to assets ratio x0.40.3 175.3%   
Return on assets %11.8-2.3 -501.3%  
Return on equity %-0.8-5.8 14.7%  
Return on capital %22.3-3.0 -741.0%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Net fx Rs m1810-   
CASH FLOW
From Operations Rs m11,754142,812 8.2%  
From Investments Rs m-561-341,946 0.2%  
From Financial Activity Rs m-6,762192,124 -3.5%  
Net Cashflow Rs m4,432-7,010 -63.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 63.67 Rs / USD

Compare ELDER PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare ELDER PHARMA With: NATCO PHARMA  GSK PHARMA  CIPLA  ABBOTT INDIA  PLETHICO PHARMA  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS